Phio Pharmaceuticals CORP 8-K filings

Phio Pharmaceuticals Corp. announced the appointment of Dr. R. Todd Plott, a dermatologist with extensive research and FDA experience, to its Board of Directors.

Phio Pharmaceuticals announced first quarter 2026 financial results, highlighting the completion of its PH-762 Phase 1b skin cancer trial and securing development agreements.

Phio Pharmaceuticals Corp. has entered into an At The Market Offering Agreement to sell up to $6.36 million in common stock.

Phio Pharmaceuticals signed a U.S. cGMP manufacturing agreement to produce PH-762 for clinical and potential commercial use, citing favorable Phase 1b signals and runway into H1 2027.

Phio Pharmaceuticals reports favorable Phase 1b data for lead cancer drug PH-762 and secures $23.7 million, extending cash runway into 2027.

Phio Pharmaceuticals announced positive safety and pathological response results from its Phase 1b clinical trial of PH-762 for skin cancer, with high response rates in the final dose cohort.

Phio Pharmaceuticals announced positive key tumor response data from its intratumoral PH-762 dose escalation cutaneous carcinoma trial, showing a 70% overall response rate for squamous cell carcinomas.

Phio Pharmaceuticals announced FDA acceptance of its PH-762 nonclinical study design, paving the way for a toxicology study in Q1 2026 and further drug development.

Phio Pharmaceuticals announced the completion of enrollment in its Phase 1b clinical trial for PH-762, an INTASYL siRNA compound targeting PD-1 for skin cancer.

Phio Pharmaceuticals announced positive clinical trial results for its lead cancer therapeutic PH-762 and secured $12.1 million in financing, extending its cash runway into H1 2027.

Phio Pharmaceuticals Corp. secured approximately $13.4 million in gross proceeds through inducement letter agreements for the exercise of existing warrants and the issuance of new Series A warrants.

Phio Pharmaceuticals announced positive pathologic results for its INTASYL PH-762 skin cancer trial, showing significant tumor clearance and a favorable safety profile at maximum dose.

Phio Pharmaceuticals announced the resignation of director Robert Ferrara and the appointment of David Deming as Lead Independent Director, reducing the Board size to five members.

Phio Pharmaceuticals Corp. stockholders approved an amendment to the 2020 Long Term Incentive Plan, increasing available shares by 950,000, and re-elected all six directors at the 2025 Annual Meeting.

Phio Pharmaceuticals announced its presentation at the H.C. Wainwright 27th Annual Global Investment Conference and the advancement of its Phase 1b clinical trial for skin cancer to the 5th cohort.

Phio Pharmaceuticals reported Q2 2025 financial results, highlighted by clinical progress for its lead cancer therapeutic PH-762 and a significant increase in cash reserves.

Phio Pharmaceuticals Corp. announced it raised approximately $2.5 million in gross proceeds by inducing the exercise of existing warrants at a reduced price and issuing a substantial number of new warrants, incurring significant fees and potential future dilution.

Phio Pharmaceuticals announced a new U.S. manufacturing agreement for its lead compound PH-762 and reported promising pathology results from its Phase 1b clinical trial, including complete and partial tumor responses in skin cancer patients.

PHIO Pharmaceuticals Corp. has set September 11, 2025, as the date for its 2025 Annual Meeting of Stockholders, necessitating revised deadlines for stockholder proposals and director nominations due to the change from the prior year's anniversary.

Phio Pharmaceuticals Corp. announced that its Safety Monitoring Committee recommended advancing its lead clinical siRNA compound, PH-762, to the fifth and final dose escalation cohort in its Phase 1b skin cancer clinical trial, citing a supportive safety profile.

PHIO Pharmaceuticals Corp. announced the appointment of Lisa Carson as VP, Finance and Administration and Principal Financial Officer, while former CFO Robert Infarinato transitions to VP, Strategic Development to focus on the broader INTASYL siRNA portfolio, following positive interim clinical trial results for PH-762.

Phio Pharmaceuticals announces encouraging Phase 1b clinical trial results for PH-762 and reports its financial results for the first quarter of 2025.

Phio Pharmaceuticals reports promising results from its Phase 1b clinical trial of INTASYL PH-762, including complete pathologic responses in patients with cutaneous squamous cell carcinoma.

Phio Pharmaceuticals has dismissed BDO USA, P.C. and engaged Grant Thornton LLP as its independent registered public accounting firm, effective April 17, 2025.

Phio Pharmaceuticals announces its INTASYL PH-762 skin cancer study will advance to the fourth dose escalation cohort after a positive recommendation from the Safety Monitoring Committee.

Phio Pharmaceuticals announces its 2024 year-end financial results and provides a business update, emphasizing the progress of its PH-762 clinical trial.

Phio Pharmaceuticals expands its Board of Directors to six members with the appointment of David H. Deming, bringing extensive experience in investment banking and asset management.

Phio Pharmaceuticals Corp. has announced a $1.83 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of warrants.

Phio Pharmaceuticals Corp. has entered into definitive agreements for a $2.5 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of warrants.

Phio Pharmaceuticals has secured $3.19 million in a registered direct offering to advance its INTASYL siRNA gene silencing technology for cancer treatment.